Jubilant Pharmova

JUBLPHARMA.NS

Noida, India· Est. 1978

jubl.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

JUBLPHARMA.NS · Stock Price

INR 981.15+113.30 (+13.06%)

Market Cap: $1.7B

Historical price data

Overview

Jubilant Pharmova's mission is to become a leading global pharmaceutical company by delivering high-quality, affordable medicines through innovation and operational excellence. The company has achieved this through strategic vertical integration, building world-class manufacturing assets for complex APIs and sterile injectables, and establishing a strong global footprint. Its core strategy focuses on deepening capabilities in high-growth specialty segments like oncology and radiopharmaceuticals, while expanding its high-margin Contract Development and Manufacturing (CDMO) business to leverage global outsourcing trends.

OncologyCentral Nervous SystemAllergy/ImmunologyInfectious DiseaseCardiovascularPain Management

Technology Platform

Integrated pharmaceutical manufacturing platform with core expertise in complex API synthesis, sterile injectables (including oncology), radiopharmaceuticals (diagnostic & therapeutic), and advanced formulation development for solid and liquid dosage forms.

Opportunities

Significant growth is anticipated from the global outsourcing trend in complex pharmaceutical manufacturing (CDMO), the expansion of high-margin specialty segments like sterile injectables and radiopharmaceuticals, and the ongoing demand for complex generics as drug patents expire.

The company's integrated model is uniquely positioned to capitalize on these concurrent market shifts.

Risk Factors

Key risks include intense pricing pressure in the generics market, stringent regulatory compliance requirements across global manufacturing facilities, execution risks associated with advancing a complex specialty pipeline, and potential supply chain or geopolitical disruptions affecting global operations.

Competitive Landscape

Jubilant Pharmova competes with large Indian generic manufacturers (e.g., Sun Pharma, Dr. Reddy's) in APIs and formulations, global sterile injectable producers (e.g., Pfizer Hospira, Fresenius), and specialized radiopharma companies (e.g., Novartis, Curium). Its competitive edge stems from vertical integration, scale in complex manufacturing, and a diversified portfolio that mitigates segment-specific competition.